Neuronal genetic rescue normalizes brain network dynamics in a lysosomal storage disorder despite persistent storage accumulation
Rebecca C. Ahrens‐NicklasiD, Luis TecedoriD, Arron F HalliD, Owen KaneiD, Richard J. ChungiD, Елена ЛысенкоiD, Eric D. MarshiD, Colleen S. SteiniD, Beverly L. DavidsoniD
Abstract
Although neurologic symptoms occur in two-thirds of lysosomal storage disorders (LSDs), for most we do not understand the mechanisms underlying brain dysfunction. A major unanswered question is if the pathogenic hallmark of LSDs, storage accumulation, induces functional defects directly or is a disease bystander. Also, for most LSDs we do not know the impact of loss-of-function in individual cell types. Understanding these critical questions are essential to therapy development. Here, we determined the impact of genetic rescue in distinct cell types on neural circuit dysfunction in CLN3 disease, the most common pediatric dementia and a representative LSD. We restored Cln3 expression via AAV-mediated gene delivery and conditional genetic rescue in a CLN3 mouse model. Surprisingly, we found that low-level rescue of Cln3 expression in neurons alone normalized clinically-relevant electrophysiologic markers of network dysfunction, despite the presence of substantial residual histopathology, in contrast to restoring expression in astrocytes. Thus, loss of Cln3 function in neurons, not storage accumulation, underlies neurologic dysfunction in CLN3 disease, implying that storage clearance may be an inappropriate target for therapy development and an ineffectual biomarker.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 13
- FWCI
- 1.70
- Field percentile
- top 17%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Lysosomal alterations and decreased electrophysiological activity in CLN3 disease (966 bp deletion, E295K) patient-derived cortical neurons
Sueanne Chear, Sharn E. Perry, … Anthony L Cook·Disease Models & MechanismsPeer-reviewed·Dec 1, 2022
- Reversible synaptic deficits in early-stage Batten disease
Masood Ahmad Wani, Chloe M. Hall, … Jakob von Engelhardt·Journal of Translational MedicinePeer-reviewed·May 20, 2026
- TRPML1 activation ameliorates lysosomal phenotypes in CLN3 deficient retinal pigment epithelial cells
D. Wuenkhaus, R. Tang, … S. Markmann·Scientific ReportsPeer-reviewed·Jul 29, 2024
- Loss of CLN3 in microglia leads to impaired lipid metabolism and myelin turnover
Seda Yaşa, Elisabeth S. Butz, … Susan L. Cotman·Communications BiologyPeer-reviewed·Oct 22, 2024
- Enteric nervous system degeneration in human and murine CLN3 disease, is ameliorated by gene therapy in mice
Ewa Ziółkowska, Letitia L. Williams, … Jonathan D. Cooper·Acta Neuropathologica CommunicationsPeer-reviewed·Dec 22, 2025
- Distinct Auditory Thalamocortical Pathologies Underlie Emerging Neurophysiological Dysfunction in a Cln3 Mouse Model of Batten Disease
Yanya Ding, Jingyu Feng, … Kuan Hong Wang·bioRxiv·Jun 4, 2026